Adding Ninlaro (ixazomib) to cyclophosphamide and dexamethasone does not improve progression-free survival for multiple myeloma patients who relapsed…
Articles by Steve Bryson, PhD
Carvykti (ciltacabtagene autoleucel; cilta-cel) has been recommended for approval in Europe by the Committee for Medicinal Products for Human Use…
Black people with multiple myeloma live longer than white patients with similar disease symptoms when both receive the same…
The therapy Sarclisa (isatuximab) extended survival by nearly seven months in relapsed/refractory multiple myeloma patients also given Pomalyst…
The U.S. Food and Drug Administration (FDA) has approved Darzalex Faspro (daratumumab and hyaluronidase), in combination with Kyprolis…
People with blood type O are significantly less likely to develop multiple myeloma,…
Xgeva (denosumab) has been approved by the China National Medical Products Administration…
Administering radiation therapy to people with relapsed or refractory (resistant) multiple myeloma…
Oncopeptides has formally opened sEAPort, its open-label expanded access program…
Janssen‘s new under-the-skin formulation of daratumumab, called Darzalex Faspro,…